GB201911517D0 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB201911517D0
GB201911517D0 GBGB1911517.9A GB201911517A GB201911517D0 GB 201911517 D0 GB201911517 D0 GB 201911517D0 GB 201911517 A GB201911517 A GB 201911517A GB 201911517 D0 GB201911517 D0 GB 201911517D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1911517.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Priority to GBGB1911517.9A priority Critical patent/GB201911517D0/en
Publication of GB201911517D0 publication Critical patent/GB201911517D0/en
Priority to PCT/GB2020/051914 priority patent/WO2021028679A1/en
Priority to JP2022508963A priority patent/JP7678793B2/ja
Priority to PH1/2022/550322A priority patent/PH12022550322A1/en
Priority to EP20758285.9A priority patent/EP4013384A1/en
Priority to KR1020227008300A priority patent/KR20220045214A/ko
Priority to AU2020328223A priority patent/AU2020328223B2/en
Priority to MX2022001724A priority patent/MX2022001724A/es
Priority to US17/632,891 priority patent/US20220265549A1/en
Priority to CN202080056792.8A priority patent/CN114286672A/zh
Priority to IL326396A priority patent/IL326396A/en
Priority to CA3144713A priority patent/CA3144713A1/en
Priority to BR112022002630A priority patent/BR112022002630A2/pt
Priority to MYPI2022000719A priority patent/MY208922A/en
Priority to ZA2022/01322A priority patent/ZA202201322B/en
Priority to IL290447A priority patent/IL290447B1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1911517.9A 2019-08-12 2019-08-12 Pharmaceutical composition Ceased GB201911517D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1911517.9A GB201911517D0 (en) 2019-08-12 2019-08-12 Pharmaceutical composition
MYPI2022000719A MY208922A (en) 2019-08-12 2020-08-12 Pharmaceutical composition comprising ensifentrine
AU2020328223A AU2020328223B2 (en) 2019-08-12 2020-08-12 Pharmaeutical composition comprising ensifentrine
US17/632,891 US20220265549A1 (en) 2019-08-12 2020-08-12 Pharmaceutical composition comprising ensifentrine
PH1/2022/550322A PH12022550322A1 (en) 2019-08-12 2020-08-12 Pharmaceutical composition comprising ensifentrine
EP20758285.9A EP4013384A1 (en) 2019-08-12 2020-08-12 Pharmaceutical composition comprising ensifentrine
KR1020227008300A KR20220045214A (ko) 2019-08-12 2020-08-12 엔시펜트린(ensifentrine)을 포함하는 약학적 조성물
PCT/GB2020/051914 WO2021028679A1 (en) 2019-08-12 2020-08-12 Pharmaeutical composition comprising ensifentrine
MX2022001724A MX2022001724A (es) 2019-08-12 2020-08-12 Composicion farmaceutica que comprende ensifentrina.
JP2022508963A JP7678793B2 (ja) 2019-08-12 2020-08-12 エンシフェントリンを含む医薬組成物
CN202080056792.8A CN114286672A (zh) 2019-08-12 2020-08-12 包含恩塞芬汀的药物组合物
IL326396A IL326396A (en) 2019-08-12 2020-08-12 Pharmaceutical preparation containing ensifentrin
CA3144713A CA3144713A1 (en) 2019-08-12 2020-08-12 Pharmaeutical composition comprising ensifentrine
BR112022002630A BR112022002630A2 (pt) 2019-08-12 2020-08-12 Composição farmacêutica em pó seco adequada para administração por inalação, inalador de pó seco e método de tratamento ou prevenção de doenças ou condições
ZA2022/01322A ZA202201322B (en) 2019-08-12 2022-01-27 Pharmaceutical composition comprising ensifentrine
IL290447A IL290447B1 (en) 2019-08-12 2022-02-08 Pharmaceutical preparation containing ensifentrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1911517.9A GB201911517D0 (en) 2019-08-12 2019-08-12 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
GB201911517D0 true GB201911517D0 (en) 2019-09-25

Family

ID=67991071

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1911517.9A Ceased GB201911517D0 (en) 2019-08-12 2019-08-12 Pharmaceutical composition

Country Status (15)

Country Link
US (1) US20220265549A1 (https=)
EP (1) EP4013384A1 (https=)
JP (1) JP7678793B2 (https=)
KR (1) KR20220045214A (https=)
CN (1) CN114286672A (https=)
AU (1) AU2020328223B2 (https=)
BR (1) BR112022002630A2 (https=)
CA (1) CA3144713A1 (https=)
GB (1) GB201911517D0 (https=)
IL (2) IL326396A (https=)
MX (1) MX2022001724A (https=)
MY (1) MY208922A (https=)
PH (1) PH12022550322A1 (https=)
WO (1) WO2021028679A1 (https=)
ZA (1) ZA202201322B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7307855B2 (ja) * 2019-10-11 2023-07-12 テレフオンアクチーボラゲット エルエム エリクソン(パブル) 無線通信ネットワークにおける設定ダウンリンク送信および動的ダウンリンク送信をハンドリングする方法および装置
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN120787157A (zh) * 2022-10-20 2025-10-14 维罗纳制药公司 使用恩塞芬汀治疗特发性肺纤维化
KR20250087621A (ko) * 2022-10-28 2025-06-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
AU2024309346C1 (en) 2023-06-26 2026-03-12 Verona Pharma Plc Particulate composition comprising ensifentrine
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
DE60005493T2 (de) 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
EP2968312B1 (en) * 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
KR20220045214A (ko) 2022-04-12
ZA202201322B (en) 2024-06-26
IL290447A (en) 2022-04-01
CN114286672A (zh) 2022-04-05
BR112022002630A2 (pt) 2022-05-03
WO2021028679A1 (en) 2021-02-18
WO2021028679A8 (en) 2022-02-24
CA3144713A1 (en) 2021-02-18
AU2020328223B2 (en) 2025-09-04
JP2022550664A (ja) 2022-12-05
US20220265549A1 (en) 2022-08-25
JP7678793B2 (ja) 2025-05-16
IL290447B1 (en) 2026-03-01
IL326396A (en) 2026-04-01
PH12022550322A1 (en) 2023-02-13
MY208922A (en) 2025-06-11
MX2022001724A (es) 2022-03-11
EP4013384A1 (en) 2022-06-22
AU2020328223A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
GB201911928D0 (en) Pharmaceutical compounds
GB202008961D0 (en) Pharmaceutical composition
IL276888A (en) Pharmaceutical compositions containing timolol
GB201911517D0 (en) Pharmaceutical composition
GB201911944D0 (en) Pharmaceutical compounds
GB201807053D0 (en) Pharmaceutical composition
GB201915273D0 (en) Pharmaceutical compounds
GB201914910D0 (en) Pharmaceutical compounds
GB201804548D0 (en) Pharmaceutical compositions
GB201915932D0 (en) Pharmaceutical compounds
IL290469A (en) Oral pharmaceutical preparation
ZA202006541B (en) Pharmaceutical composition comprising brexpiprazole
SMT202400011T1 (it) Composizione farmaceutica
GB201901989D0 (en) Pharmaceutical combinations
GB201808571D0 (en) Pharmaceutical compositions
IL285728A (en) Pharmaceutical composition
IL291570A (en) Pharmaceutical preparations
GB201808567D0 (en) Pharmaceutical compositions
PL3949952T3 (pl) Kompozycja farmaceutyczna
SG11202103374TA (en) Pharmaceutical composition
PL4027974T3 (pl) Kompozycja farmaceutyczna zawierająca p-boronofenyloalaninę
GB202010340D0 (en) Pharmaceutical composition
EP3903782A4 (en) PHARMACEUTICAL COMPOSITION
GB201912686D0 (en) Pharmaceutical composition
GB201908003D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)